Literature DB >> 6605799

Correlation between lymphocyte-mediated auto-tumor reactivities and clinical course. I. Evaluation of 46 patients with sarcoma.

F Vánky, J Willems, A Kreicbergs, T Aparisi, M Andréen, L A Broström, U Nilsonne, E Klein, G Klein.   

Abstract

T-cell-enriched blood lymphocyte populations from 24 osteosarcoma and 22 soft-tissue sarcoma patients were assayed at the time of surgery for proliferative response to, and/or cytotoxic potential against autologous tumor cells. Tumor-free period and survival of the patients were correlated with the results obtained in the in vitro tests. The observation time was between 18 and 118 months (mean 62) for the osteosarcoma patients and between 18 and 72 (mean 42) for the patients with soft-tissue sarcoma. In both groups tumor-free period and survival were longer for those individuals who had auto-tumor reactivity. In the non-reactive group, all patients died within 3 years. Almost all patients had cytotoxicity against K562.

Entities:  

Mesh:

Year:  1983        PMID: 6605799     DOI: 10.1007/bf00199899

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  14 in total

1.  Osteosarcoma. A review of 96 cases.

Authors:  A LINDBOM; G SODERBERG; H J SPJUT
Journal:  Acta radiol       Date:  1961-07       Impact factor: 1.990

2.  Stimulation of lymphocytes by autochthonous cancer.

Authors:  J Stjernswärd; F Vánky
Journal:  Natl Cancer Inst Monogr       Date:  1972-12

3.  Soft part sarcomas revisited. Review and comparison of a second series.

Authors:  H W Ferrell; W J Frable
Journal:  Cancer       Date:  1972-08       Impact factor: 6.860

4.  Osteogenic sarcoma. A study of six hundred cases.

Authors:  D C Dahlin; M B Coventry
Journal:  J Bone Joint Surg Am       Date:  1967-01       Impact factor: 5.284

5.  Adjuvant interferon treatment of human osteosarcoma.

Authors:  H Strander; U Adamson; T Aparisi; L A Broström; K Cantell; S Einhorn; K Hall; S Ingimarsson; U Nilsonne; G Söderberg
Journal:  Recent Results Cancer Res       Date:  1978

6.  Lymphocyte cytotoxicity against autologous tumour biopsy cells in humans.

Authors:  B M Vose; F Vanky; E Klein
Journal:  Int J Cancer       Date:  1977-10-15       Impact factor: 7.396

7.  Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation stimuli required for expression.

Authors:  E L Reinherz; P C Kung; J M Pesando; J Ritz; G Goldstein; S F Schlossman
Journal:  J Exp Med       Date:  1979-12-01       Impact factor: 14.307

8.  Specificity of auto-tumor cytotoxicity exerted by fresh, activated and propagated human T lymphocytes.

Authors:  F Vánky; E Klein
Journal:  Int J Cancer       Date:  1982-05-15       Impact factor: 7.396

9.  The prognosis in osteosarcoma: Norwegian National Data.

Authors:  S Harvei; O Solheim
Journal:  Cancer       Date:  1981-10-15       Impact factor: 6.860

10.  Specific and non-specific lymphocyte cytotoxicity in colon carcinoma.

Authors:  B M Vose; P Gallagher; M Moore; P F Schofield
Journal:  Br J Cancer       Date:  1981-12       Impact factor: 7.640

View more
  12 in total

1.  Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells.

Authors:  P Allavena; P Lo Presti; M Di Bello; V Lucchini; A Lissoni; G Zanetta; C Mangioni; A Mantovani
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 2.  Biological significance of autologous tumor-killing activity and its induction therapy.

Authors:  A Uchida
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

3.  The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumour cells.

Authors:  F Vánky; P Wang; E Klein
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 4.  Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.

Authors:  B M Vose
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  DR antigens expressed on tumor cells do not contribute to the blastogenetic response of autologous T cells.

Authors:  F Vánky; E Klein; J Willems
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

6.  Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study.

Authors:  A Balsari; R Marolda; C Gambacorti-Passerini; G Sciorelli; G Tona; E Cosulich; D Taramelli; G Fossati; G Parmiani; N Cascinelli
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

7.  In vitro generation of tumour-specific lymphocyte reactivity to colonic carcinoma cells. Comparison with normal colonic mucosa cells.

Authors:  M Kuppner; S Wilkinson; E Casson; O Eremin
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Induction of human glioma-specific cytotoxic T-lymphocyte lines by autologous tumor stimulation and interleukin 2.

Authors:  S Miyatake; H Handa; J Yamashita; T Yamasaki; M Ueda; Y Namba; M Hanaoka
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

9.  Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture--no correlation with the postsurgical clinical course.

Authors:  F Vánky; E Klein; J Willems; K Böök; T Ivert; A Péterffy; U Nilsonne; A Kreicbergs
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

10.  Lysis of autologous tumor cells by blood lymphocytes tested at the time of surgery. Correlation with the postsurgical clinical course.

Authors:  F Vánky; E Klein; J Willems; K Böök; T Ivert; A Péterffy; U Nilsonne; A Kreicbergs; T Aparisi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.